The US Supreme Court should decline to review a generic drug labeling fight between Amarin and Hikma Pharmaceuticals because ...

American Society of Gene & Cell Therapy meeting sees 10% drop in attendance. Notable absences include FDA officials, David ...

Rocket Pharmaceuticals reports early success in gene therapy trial for heart condition PKP2-ACM, with 3 patients showing ...

The Trump administration is partnering with Mark Cuban’s compounding business and four other entities to improve the ...

BioMarin plans to buy Boston-based Inozyme Pharma and its Phase 3 enzyme replacement therapy for about $270 million, the ...

FDA lifts hold on Scynexis' ibrexafungerp Phase 3 fungal infection trial, but GSK plans to end study. Incyte's Zynyz gets FDA ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down amid market challenges and a clinical disappointment for CagriSema.

Leo Pharma is doing an extensive revamp of its leadership team as it splits product strategy and international operations ...

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for ...

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored ...

A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...